Yazar "Tabak, Fehmi" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Efficiency and safety of direct acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey(Elsevier, 2019) Kurtaran, Behiçe; Sarıgül, Figen; Çabalak, Mehmet; Kaya, Sibel; Sarı, Nagehan Didem; Karsen, Hasan; Tabak, Fehmi…Öğe The evaluation of exposure to hepatitis A virus in HBsAg-positive persons: A multicentre study from Turkey(Journal of Pure and Applied Microbiology, 2014) Çelen, Mustafa Kemal; Türker, Kamuran; Öztoprak, Nefise; Şener, Alper; Tuna, Nazan; İnce, Nevin; Tabak, FehmiChronic hepatitis B is a major public health problem in our country. Hepatitis A vaccination in HBV carriers who did not encounter with Hepatitis A virus is also significant. We aimed to evaluate the rate of exposure to HAV in HBsAg-positive persons, and the distribution of seronegative individuals according to age groups. Medical records of 4793 patients from 14 centers who were positive for hepatitis B surface antigen (HBsAg). A total 3514 cases (73.3%) were male and 1279 (26.7) were female. The HBsAg positive patients who were previously tested for HAV IgG at the time of firstly admitted to a center. HBsAg positive patients who were previously not tested for HAV IgG were tested and these . patients were confirmed serologically for HAV. The distribution of cases according to age were determined. In this study, 4793 HBsAg-positive patients were evaluated. The ratio of testing of anti-HAV IgG was very low during the first visit (54.2%). Seronegativity was highest in the age group under 19 years of age (26.2%) followed by 20-25 age group (15.5%) and 26-29 age group (12.5%). Testing of HAV serology should not be ignored in especially HBsAg-positive young adults and seronegative young adults should be vaccinated.